Mnkd has a great diabetic partner, SNY.
Share price is ridiculously low, even a Buyout is over current market cap
They started a slow launch, just introducing AFrezza to a group of docs
when they Advertise, this will move like gangsbusters
They had to do a controlled launch because 1 production line could support the demand anyways.
Lines 2-3 increased production in preparation for demand increase
Here's a catch.....wait for it (even if Afrezza turns out to be a flop which i doubt because I have seen first hand on how it works, you will still have all they hypes with advertisements, plenty of time to get out for profits).
But if Afrezza is a success, in short term, the gain is 4-5 folds, long term is 20-100 folds
100 mill shares short coverage will have to buy; $1 is minimum, someone will buy technoshphere for at least a buck.
Thus, very little or zero risk here and huge upside.
Shorts brought it down to the 3's to cover and as soon as it hit 4, it was manipulated back down to cover again. They are shaking the trees really vigourously now. Any longs who can withstand this either lose it all or become very rich. This is the last ditch effort from the shorts before the floodgate of Afrezza PR/advertisement and Line 2-3 fully opened to accommodate the demand.
management compares afrezza to iphone; they are correct. If this picks up the market shares of 450 million diabetics world wide; every diabetics will want to inhale insulin because no psychopath will want needles. AFREZZA IS A CONSUMER PRODUCT, NOT a doctor's product. Doctors don't care if they give injection or inhaltion but the patients will care if their bellies or arms are getting stuck with needles. Thus, you have to wait for advertisement to decide how Afrezza does in the market.
Currently there are 225,000 docs capable of prescribing Afrezza but only a handful of endocrinologists have been approached by SNY. The question that everyone should ask at any mnkd conference is how many docs know about Afrezza? If ONLY 200-300 docs have been educated by SNY and they have been prescribing 200 scripts/week; this is 100% megablockbuster. Once they open the floodgate to 225,000 PCPs and endocrinologists, then what we have is the biggest selling drug of all time.
This slow controlled launch is just one big ploy to create a perception of low demand for Afrezza which sets up for sell offs and buyout to happen. Call around and ask why haven't your local PCPs or endocrinologists heard of Afrezza?
We all know that Feuerstein and Shkrelli wanted afrezza to fail and these guys went as far as trying to convince the Fda to kill afrezza. Revenge?
Mnkd sent out $7.1 million of afrezza at cost but Sny only sold $1 million at market value, so where is the rest of the $7.1 million of afrezza, at cost? All samples? So, what's gonna happen when the samples run out? Will there be a huge surge in demand? Did Sny and Mnkd teamed up to kill shorts? They just opened up lines 2 and 3 to increase afrezza production. Stay tuned folks, shorts are about to get massively squeezed of a life time.
I am long because my diabetic friend is using Afrezza and she loves it. That is the only thing I can base on; I have nothing else going for me.
if only 100-300 docs have the knowledge of Afrezza and they are writting about 200 scripts each week; this translates to 1-2 scripts/doc/wk. Extrapolate that to 220,000 PCPs and 5,000 endocrinologists when the floodgate is opened, then you will have 225,000-500,000 scripts/wk. Afrezza will probably be the best selling drug of all time.
Think about it folks, why has the number of scripts been consistently about 200/wk? The only explanation is the number of docs prescibing has not changed week after week. That means SNY only are teaching a set number of docs; they have not increased the number of docs exposed to AFrezza at all. Theoretically the number of docs should increase with time and so as the scripts number, but why is the script # remaining the same week after week?. Something is shaddy here with sNY. buyout!!!
It doesn't make any sense for a guy at his age who already owns 150 mil shares wanting to own 250 mil more shares? What is gonna do with all that money? He would rather share the wealth and claim his legacy; instead of burying himself with greed. C'mon have some common sense.
Longs who held after FDA approval see Afrezza as a blockbuster. This is a slow launch without any PR or advertisement, and they haven't even manufactured enough Afrezza to meet any expectation of high volume. Thus, you have to wait for consumer advertisments and full launch. In the mean time, Afrezza is gaining traction, increasing scripts by factor of 50-100%.
Shorts on the other hand, was 70 million shares in the hole before FDA approval, so they hoped that Afrezza would get killed by the FDA. But it didn't, so now we have manipulation with 40+ more million shares used to manipulate price down. I think they dug themselves into their own graves.
looks like they blew their wad for nothing. it went back up. Someone has been sitting around for nearly 3-4 weeks, just collecting cheap shares.
there is no motive for an 89 yo billionaire who already owns 150 mil shares wanting to own 250 mil more shares. Burry himself with cash in his last decade of life doesn't make sense. Sharing the wealth and carrying legacy is more important at this stage.
if it stays in the 4's, it is time to add more shares. We are at the bottom, time will get better and better with scripts#
Imagine the scenario in which SNY has been selling Afrezza ONLY to 300 docs and these docs write about 200 scripts/wk. That is 2 scripts/doc/wk; imagine when the floodgate of 225,000 docs will have been educated about Afrezza! And they will write about 225,000-500,000 scripts each week. SNY could acquire Afrezza for a fraction of the price. What a game they played on investors and shorts!!!!!
but there is also a drawback in AFREZZA BEING A CONSUMER PRODUCT, it still relies on doctors prescribing the drug to patients, so you have to give enough time for the docs to familiarize themselves with the drug. You can't massively launch Afrezza with PR and Advertisements and drive millions of diabetics to the doctors when the doctors aren't familiar with the drug. NO doc is ever goiing to prescribe a drug that they have no knowledge about; their license is on the line. Thus, you have to give it time for doctor's education and advertisement to happen.
Remember, Afrezza is not a cure or the ONLY diabetic treatment in the market. Thus, no doc is ever going to prescribe it, unless they know about it. It's not a cure or ONLY option drug, that is forced upon patients with the disease.
I am long, and I sense that this is a lie. 99% of docs have not heard of AFrezza. I have doctor friends who are family practitiioners living in major cities, none of them have seen or heard of AFrezza. There are 225,000 of these guys ready to prescribe but they can't because no one has heard of AFrezza. For sure the patients are unaware of AFrezza. So, please do not post such lies, unless you are lucky that you know the very few endocrinologists who have been educated by SNY reps.
it doesn't mean anyuthing, looke at the share price and it's dirt cheap, so he changed his mind. Any logical person would, take it as that! don't read too much into it.